Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/handle/10553/77560
Title: 1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: Rodriguez Abreu, D.
Garassino, M.C.
Esteban, E.
Speranza, G.
Felip, E.
Domine, M.
Hochmair, M.J.
Powell, S.F.
Cheng, S.Y.-S.
Bischoff, H.
Peled, N.
Hui, R.
Reck, M.
Garon, E.B.
Boyer, M.
Grossi, F.
Jennens, R.
Yang, J.
Pietanza, M.C.
Gadgeel, S.M.
UNESCO Clasification: 320101 Oncología
Issue Date: 2018
Journal: Annals of Oncology 
Conference: European-Society-for-Medical-Oncology Asia Congress 
Abstract: In KEYNOTE-189 (NCT02578680), pembro plus pem and platinum provided superior OS (HR 0.49, P < .00001) and PFS (HR 0.52, P < .00001) and had manageable safety vs placebo plus pem and platinum as first-line therapy for metastatic nonsquamous NSCLC. In an exploratory analysis, we assessed outcomes by investigator’s choice of carboplatin (carbo) or cisplatin (cis).
URI: https://accedacris.ulpgc.es/handle/10553/77560
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy292.086
Source: Annals of Oncology [0923-7534], n. 29 (supl. 8)
Appears in Collections:Actas de congresos
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.